Zambon S.p.a.

Advanced Accelerator Applications Sa

Molteni Therapeutics S.r.l.

L. Molteni & C. Dei Fratelli Alitti—società Di Esercizio S.p.a.

Gian Maria Rossolini

Lucia Pallecchi

Francesco Sergio

Gabrio Roncucci

Donata Dei

Giacomo Chiti

Lia Fantetti

Giulio Jori

Franck Martin

Francesco Giuliani

Stefano Cencioni

Antonella Colagrande

Maria Cristina Thaller

Marco Maria D'Andrea

A synergistic pharmacological association of N-acetylcysteine (NAC) and colistin for use in the treatment of a bacterial infection caused by one or more pathogens selected fromandstrains, in particular a bacterial infection associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising cystic fibrosis (CF), bronchiectasis non CF and chronic obstructive pulmonary disease COPD is described.

Association of N-acetylcysteine and colistin for use in bacterial infections

The present invention relates to N-acetylcysteine for the use in the treatment of bacterial infections caused by a pathogen selected fromcomplex (BCC) and() strains.

N-acetylcysteine for use as antibacterial agent

A synergistic pharmacological association of N-acetylcysteine (NAC) and colistin for use in the treatment of a bacterial infection caused by one or more pathogens selected fromandstrains, in particular a bacterial infection associated with a respiratory tract disease, such as a chronic respiratory tract disease comprising cystic fibrosis (CF), bronchiectasis non CF and chronic obstructive pulmonary disease (COPD) is described.

The present invention relates to pharmaceutical compositions comprising metal phthalocyanine analogues of formula (I) and metal chelating compounds having a good bioavailability and enhanced photoinactivation properties against Gram negative bacteria; and to their use for in vivolex vivo applications, such as blood and blood derivatives sterilization. 

Antibacterial compositions comprising metal phthalocyanine analogues

The present invention relates to a method of producing a recombinant protein comprising using a selection method other than antibiotics. In particular, it relates to a stable host/vector system based on the pyrC gene complementation designed to produce high level of heterologous recombinant protein in The expression system of the present invention allows rapid selection of plasmid containing cells during the cloning phases and lead to high protein expression during fermentation. This system has a strong selective efficiency, especially during the induction phase, leading to the selection of an almost homogeneous and stable plasmid bearing cell population. Moreover the productivity of the culture is to a large extent better than the one based on antibiotic resistance.This elevated vector stability combined with its high productivity fulfils the requirements for heterologous protein production into an industrial level.

[object Object]

Growing community of inventors

Siena, Italy

Gian Maria Rossolini